Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy
NCT01906632 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2024-02-07
Summary
To investigate gene expression profile and immunological associated analysis relating to immunotherapy response of patients with malignant tumor after DC-CIK immunotherapy.
Conditions
- Malignant Tumor
Interventions
- BIOLOGICAL
-
DC-CIK Immunotherapy
Sponsors & Collaborators
-
Capital Medical University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-05-31
- Primary Completion
- 2022-12-30
- Completion
- 2023-06-30
Countries
- China
Study Locations
More Related Trials
-
DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma
NCT00862303 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors
NCT04292769 ·Status: UNKNOWN ·Phase: PHASE3
-
DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma
NCT01924156 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric Cancer
NCT01637805 ·Status: UNKNOWN ·Phase: PHASE1
-
Engineered Immune Effectors Against Cervical Cancer
NCT03362619 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Phase I Trial of CEA Specific AAV-DC-CTL Treatment in Stage IV Gastric Cancer
NCT02496273 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Impaired Immunity in Patients With Cancer: Influence of Cancer Stage, Chemotherapy, and Cytomegalovirus Infection
NCT00521287 ·Status: UNKNOWN ·Phase: PHASE2
-
DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML
NCT01898663 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors
NCT05528341 ·Status: RECRUITING ·Phase: PHASE1
-
Study of DC-CIK to Treat Colorectal Cancer
NCT01839539 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of DC-CIK to Treat Hepatocellular Carcinoma
NCT01821482 ·Status: UNKNOWN ·Phase: PHASE2
-
NK Cells Infusion for Advanced Malignancies
NCT03619954 ·Status: UNKNOWN ·Phase: PHASE1
-
DC Vaccine Combined With CIK Cells in Patients With SCLC
NCT02688673 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
GI Complications in Cancer Immunotherapy Patients
NCT02784366 ·Status: UNKNOWN
-
Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC
NCT03360630 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors
NCT06509490 ·Status: RECRUITING ·Phase: NA
-
Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients
NCT02766348 ·Status: UNKNOWN ·Phase: PHASE2
-
A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer
NCT06530082 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma
NCT01240005 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Neoantigen-expanded Autologous Immune Cell Therapy
NCT05020119 ·Status: UNKNOWN ·Phase: PHASE1
-
The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors
NCT03047811 ·Status: UNKNOWN ·Phase: NA
-
Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor
NCT04214717 ·Status: UNKNOWN ·Phase: NA
-
Immune Profiling for Cancer Immunotherapy Response
NCT06116032 ·Status: RECRUITING
-
CX3CR1+T Cell Predict Immunotherapy Efficacy
NCT06054152 ·Status: COMPLETED
-
Autologous Natural Killer T Cells Infusion for the Treatment of Cancer
NCT01801852 ·Status: UNKNOWN ·Phase: NA